REGENXBIO has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy.

Fast Track designation aims to facilitate the development and expedite the review of new therapeutics that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Therapies granted this designation are given the opportunity for more frequent interactions with the FDA and may qualify for priority review. The FDA has granted RGX-202 Orphan Drug Designation and Rare Pediatric Disease Designation.

“Fast Track designation, along with our capabilities to conduct our clinical trials using commercial-scale cGMP material, will further support the efficient development of RGX-202 from clinic to commercial readiness.

RGX-202 is a key part of our ‘5×25’ strategy, and we look forward to continuing to work closely with the FDA and the Duchenne community as we advance a highly differentiated product candidate developed with the potential to make a meaningful difference for patients. We look forward to reporting initial data from our clinical trial of RGX-202 in the second half of this year.” 

Kenneth T. Mills, President, and Chief Executive Officer of REGENXBIO

There’re currently no clinical trials for RGX-202 in Canada, however, Defeat Duchenne Canada will share the results of the trial as soon as the information is available. Join us on November 4-5, 2023, for the Family Forum where REGENXBIO will provide an update for our Canadian community.